Research programme: deuterium stabilised PUFAs - Retrotope

Drug Profile

Research programme: deuterium stabilised PUFAs - Retrotope

Alternative Names: 11,11-,14,14 tetra-deutero-linolenic acid ethyl ester, an omega 3 polyunsaturated fatty acid; RT 002 - Retrotope

Latest Information Update: 01 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Retrotope
  • Class Unsaturated fatty acids
  • Mechanism of Action Lipid modulators; Lipid peroxidation inhibitors; Unsaturated fatty acid modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alzheimer's disease; Friedreich's ataxia; Mitochondrial myopathies; Parkinson's disease; Retinal disorders

Most Recent Events

  • 10 Nov 2017 Retrotope files for patent protection for amino-acids and 6 D-PUFA treatment applications (Retrotope website, November 2017)
  • 10 Nov 2017 Retrotope files for patent protection for isotopically modified fatty acids, lipid drugs (Retrotope website, November 2017)
  • 10 Nov 2017 Retrotope has patent protection for isotopically modified fatty acids, lipid drugs for the treatment of retinal diseases, mitochondrial deficiency, hepatic disorders, lipidemias, cardiac-related risk factors and neurodegenerative and neuromuscular diseases until 2032 and for mitochondrial diseases until 2030 (Retrotope website, November 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top